Trial Profile

A Randomized, Double-Blinded, Controlled Trial Evaluating Recombinant Human Platelet-Derived Growth Factor B (rhPDGF-BB)-Enhanced Wound Matrix in the Reconstruction of Full-Thickness Head or Neck Defects Following Skin Cancer Excision

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Aug 2026 According to Lynch Regenerative Medicine media release, company announced the completion of enrollment in this trial. Patients are followed over the studys eight-week assessment period, after which data will be analyzed.The use of rhPDGF-BB being evaluated in this study is investigational and has not been approved by the U.S. Food and Drug Administration for this indication. The study remains ongoing, and no conclusions regarding safety or effectiveness can be drawn until the study is completed.
20 Jul 2026 Status changed from recruiting to completed.
23 Mar 2026 Planned End Date changed from 1 May 2026 to 1 Jun 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com